🔗 Share this article

Given that the US undertakes historic changes to its vaccination recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines throughout the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Schedule

Agency leaders had intended to unveil sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of step with a large portion of the world with little proof for improved outcomes. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood shot schedules in the US to become more in line with Denmark, a society with comprehensive healthcare and a population approximately the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Questions Over Background

Høeg has no apparent track record in drug development, regulation or leadership, which has been standard for past heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in leading a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “grasp legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Objectively, she lacks the type of experience that former directors who ran the center have had.”

CDER has an immense workload at the agency, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and each of these must be supervised,” Dr. Woodcock explained. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant management aspect to the role, which manages over 5,000 staff members. “It is a massive management job, if you do it right,” she said.

Agency Reaction and Controversial Programs

Regarding concerns about Høeg’s fitness for the role and whether this appointment signifies more teamwork among agency officials on vaccines, a representative said that the “concerns stem from incorrect assumptions”.

“Her resume is consistent with the responsibilities of her job,” the representative stated, citing the time Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious one-day medication authorization process that allegedly troubled her preceding directors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the agency seems to be moving towards more relaxed rules of all drugs, aside from immunizations.”

Documented History on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, some experts have noted. She published a analysis using unconfirmed public submissions to estimate the frequency of heart inflammation after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new government featured changing rules for novel immunizations and halting “non-essential” vaccines, she stated after the election on a podcast. At the agency, Høeg has according to sources proposed excluding young men from getting Covid vaccinations.

“She is an thorough ideologue who begins with her conclusions and works backwards to accommodate the data in a extremely disingenuous, untruthful manner,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of other contrarians, {like|